

1 ***Case report:***

2 **The impact of antibiotics on the presence of the protozoan anaerobe**

3 ***Blastocystis* and the surrounding microbiome: a case study**

4

5 Jamie M. Newton<sup>1</sup>, William JS. Edwards<sup>1</sup>, Gary Thompson<sup>2</sup>, Eleni Gentekaki<sup>4,5</sup>, Anastasios

6 D. Tsaousis<sup>1\*</sup>

7

8 <sup>1</sup> Laboratory of Molecular and Evolutionary Parasitology, RAPID group, School of  
9 Biosciences, University of Kent, Canterbury, UK;

10 <sup>2</sup> NMR Facility, School of Biosciences, University of Kent, Canterbury, CT2 7NJ, UK

11 <sup>3</sup> East Kent Hospitals University NHS Trust, Ashford

12 <sup>4</sup> School of Biosciences, University of Kent, Canterbury, CT2 7NJ, UK

13 <sup>5</sup> University of Nicosia School of Veterinary Medicine, 2414, Nicosia, Cyprus;

14

15 \*Corresponding author: Dr. Anastasios D. Tsaousis: [a.tsaousis@kent.ac.uk](mailto:a.tsaousis@kent.ac.uk)

16

17

18

19

20

21

22

## 23 **Abstract**

24 Background: *Blastocystis*, the most prevalent eukaryotic gut microbe in humans, has a global  
25 distribution. Studies have linked its presence with distinct gut microbiome and metabolome  
26 profiles compared to those where the organism is absent. However, the in vivo effect of  
27 antibiotics on *Blastocystis* and the surrounding gut microbiome remains understudied. This  
28 case study aimed to explore how antibiotic consumption influences the presence of  
29 *Blastocystis* and the subsequent changes in the gut microbiome and metabolome of an  
30 individual with irritable bowel syndrome (IBS).

31 Methods: Stool samples from an IBS patient, collected at various time points, were tested for  
32 *Blastocystis* presence using RT-PCR targeting the *SSUrRNA* gene, followed by sequencing of  
33 positive samples. Illumina sequencing determined the gut microbiome composition, while  
34 one-dimensional proton NMR spectroscopy analysed the metabolome composition. Statistical  
35 analyses were conducted to identify relationships between antibiotic consumption, bacterial  
36 diversity, metabolome composition, and *Blastocystis* presence.

37 Results: Antibiotics significantly impacted the gut microbiome, with diversity declining early  
38 in the antibiotic course, then recovering later and post-course. *Blastocystis* was detected early,  
39 late, and post-course but not mid-course, coinciding with the decline in bacterial diversity. No  
40 significant differences were observed between *Blastocystis*-positive and *Blastocystis*-negative  
41 samples. However, bacterial composition significantly differed between samples collected  
42 before, early, and after the antibiotic course compared to those collected mid-course.  
43 Metabolite groups, including short-chain fatty acids, amino acids, and succinate, exhibited  
44 changes throughout the antibiotic course, indicating that gut metabolite composition is  
45 affected by antibiotic consumption.

46

47 Discussion/Conclusion: While antibiotics did not significantly impact *Blastocystis*  
48 colonisation, they did cause a mid-course decline in microbial diversity and *Blastocystis*  
49 presence. The study also revealed significant alterations in important metabolites such as  
50 SCFAs and amino acids throughout the antibiotic course, with an altered metabolome  
51 observed post-course. This case study underscores the complex interactions between  
52 antibiotics, gut microbiota, and metabolites, highlighting the resilience of *Blastocystis* in the  
53 gut ecosystem.

54

55

56

57

58

59

60

61

62

63

64

65

66

## 67 **Introduction**

68 The gut microbiome and metabolome are crucial influencers of gastrointestinal (GI) health,  
69 and their interactions can be better understood by studying them in tandem [1]. This dual  
70 approach is particularly important when investigating GI health differences across various  
71 cohorts or when external factors influence the GI tract. For example, a previous  
72 metabolomics study using <sup>1</sup>H Nuclear Magnetic Resonance (NMR) spectroscopy revealed  
73 significant differences in stool metabolite composition between individuals with diarrhoea  
74 and healthy controls and between *Blastocystis* carriers and non-carriers [2]. Understanding  
75 these interactions can provide deeper insights into the complex dynamics of gut health and  
76 disease.

77 *Blastocystis* is a eukaryotic microbe that resides in the GI tract and has a global distribution in  
78 a broad range of animal hosts [3], [4]. Epidemiological studies and phylogenetic analysis of  
79 the small subunit ribosomal RNA (SSU rRNA) gene have revealed over 44 different subtypes,  
80 twelve of which STs 1-9, 12, 16, 23 have been identified in human stool samples [5], [6], [7],  
81 [8], [9]. *Blastocystis* was initially designated as a parasite and linked with IBS and other  
82 gastrointestinal disorders [10], [11]; however, more recent studies have indicated a negative  
83 correlation between the presence of the organism and gastrointestinal symptoms [8], [9], [12],  
84 [13], () muddling its association with disease. *Blastocystis*' genetic diversity further  
85 complicates interpretations, with many studies finding no relationship between inter and  
86 intra-subtype diversity and disease [9], [12].

87 Nonetheless, specific microbial profiles have been associated with the organism. For  
88 instance, *Blastocystis* presence is more common in the *Ruminococcaceae* and *Prevotella*  
89 enterotypes, rather than *Bacteroides*, and associated with higher richness and diversity, which

90 can be an indicator of good GI health [8], [14], [15]. At the level of subtype, *Blastocystis* ST3  
91 and ST4 have been shown to have an inverse relationship with *Akkermansia* abundance, an  
92 indicator of GI health [8]. Whether *Blastocystis* is a gut ecosystem engineer, a simple  
93 colonizer or just a passenger is still unknown.

94 Individuals with irritable bowel syndrome (IBS) have been known to have distinct gut  
95 bacterial compositions/profiles to their non-IBS counterparts, making IBS treatment with  
96 antibiotics a potential influencing factor [16], [17], [18], [19]. *In vivo* and *in vitro* studies  
97 have indicated that the gut microbiomes of individuals colonised with *Blastocystis* show a  
98 decline in abundance of genera such as *Bifidobacterium* and *Lactobacillus* [15], [20], [21].  
99 *Bifidobacterium* has a role in immunomodulation and protection of the GI epithelial cells  
100 [20], [22], [23]. Therefore, the results of these studies could link *Blastocystis* to dysbiosis-  
101 induced GI symptoms and possibly IBS.

102 Antibiotic administration has been an effective treatment for some IBS cases and other GI  
103 conditions, while metronidazole, ciprofloxacin and rifaximin have been effective at  
104 decreasing the severity of symptoms in many clinical trials [18], [19], [24], [25], [26].  
105 However, as our understanding of the gut microbiome's role in gastrointestinal health  
106 deepens, the impact of antibiotics on gut microbiota modulation is receiving closer scrutiny.  
107 Several studies have detected significant changes in the gut microbiome composition during  
108 antibiotic treatment and, occasionally, microbiome recovery after treatment [27], [28], [29].

109 In this case study, we monitored the metabolome and the bacterial gut microbiome  
110 composition of a *Blastocystis*-positive IBS patient during a 14-day course of antibiotics. We  
111 also analysed *Blastocystis* presence over this 14-day period and how it is impacted by  
112 antibiotic treatment. The subject's gut microbiome and metabolome composition were also

113 analysed following the termination of the antibiotic course to monitor microbial diversity  
114 recovery after *Blastocystis* detection.

115

## 116 **Materials and Method**

### 117 Ethics approval

118 The study was conducted within the guidelines established in IRAS ethics approvals 274985  
119 and 286641, following a review by an ethics committee and applying suggested amendments  
120 to comply with ethical standards. The UK National Ethic committees of Health Research  
121 Authority (HRA) and Health and Care Research Wales (HCRW) under the umbrella of NHS  
122 Health Research Authority gave ethical approval of this work.

123

### 124 Participant recruitment and sample collection

125 The study subject, previously diagnosed with IBS, presented to a hospital in the Kent county  
126 (South East England) with gastrointestinal symptoms and was put on a 14-day course of  
127 antibiotics. These included 500 mg Amoxicillin (a 3<sup>rd</sup> generation penicillin antibiotic) x 2 and  
128 500 mg Clarithromycin (a 2<sup>nd</sup> generation macrolide antibiotic). Daily doses of 30 mg  
129 Lansoprazole (proton pump inhibitor) x 2 was also prescribed. The subject was in their 40s  
130 (41 to 45) with a BMI of 29 and a mixed diet. The subject was provided with faeces catchers  
131 (Zymo Research Cat No R1101-1-10) and two types of collection tubes, one containing 5 ml  
132 DNA/RNA shield (Zymo Research Cat No R1100-250) and the other containing 5 ml of 50%  
133 methanol. Each faecal sample was distributed in the two tubes. Faecal samples were collected  
134 just before the commencement of the treatment course, then on D2 then once daily for the  
135 remainder of the first week, then once on D8, D10 and D15 (the day after the completion of

136 the course) for the following week. Follow-up samples were then collected at D30 and D3M  
137 (3 months after course start). The samples were stored in their respective tubes in DNA/RNA  
138 shield or methanol at -80°C.

139

#### 140 DNA extraction

141 200 mg solid stool stored in DNA/RNA shield or 200 µl liquid stool were added to 200 µl  
142 PBS (pH 7.4 RNAase free). The samples were then centrifuged for 10 minutes at 10,000 x g  
143 at room temperature (RT). The pellet was then resuspended in the supernatant and the DNA  
144 was extracted using the QIAamp PowerFecal Pro DNA Kit (Qiagen; Cat. No: 51804)  
145 following the manufacturer's protocol, and 50 µl DNA was eluted.

146

#### 147 qPCR and *Blastocystis* detection

148 For *Blastocystis* detection, a 350 bp region of the *SSU* rRNA gene was targeted using a  
149 reaction mixture of 2 µl DNA, 500 nM of primer set PPF1 (fwd) (5'-  
150 AGTAGTCATACGCTCGTCTCAAA-3') and R2PP (rvs) (5'-  
151 TCTTCGTTACCCGTTACTGC-3') and 5 µl SYBR green making a full reaction volume of  
152 10 µl. The qPCR was run on a Quantstudio-3 real-time PCR machine with the following  
153 program: initial denaturation 95 °C for 5 minutes, then 45 cycles of initial denaturation 95°C  
154 for 5 seconds, annealing 68 °C for 10 seconds, extension 72°C 10 seconds then a final  
155 extension of 72 °C for 15 seconds.

156

#### 157 Sequencing and Subtype annotation

158 Bi-directional Sanger sequencing using the set of primers for the qPCR reaction was  
159 outsourced to and performed by Eurofins (UK). The forward and reverse nucleotide  
160 sequences were then assessed and trimmed using SnapGene Viewer Version 6.2.2  
161 (<https://www.snapgene.com/snapgene-viewer>). The final trimmed consensus sequences were  
162 then used as queries to check for contamination using the Basic Local Alignment Search Tool  
163 (BLAST) from the National Centre for Biotechnology Information (NCBI)  
164 (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>). Once the identity of the sequence was confirmed as  
165 *Blastocystis*, the subtype was assigned using the curated database pubMLST  
166 (<https://pubmlst.org/organisms/blastocystis-spp>).

167

#### 168 16S rRNA gene amplicon sequencing

169 Novogene outsourced the high-throughput amplicon sequencing. The protocol used was  
170 based on Caporaso et al [30]. [] with some modifications. One ng DNA from extracts was  
171 used, fragmented, and then adapted for paired-end sequencing. The DNA was amplified  
172 using the primer pair 515F GTGCCAGCMGCCGCGGTAA and 907R  
173 CCGTCAATTCCTTTGAGTTT, which amplifies the hypervariable region and then  
174 sequenced on the Illumina NovaSeq platform.

175 The raw reads were classified using the Lotus2 software [[31]]. The parameters and tools  
176 used are as follows: Chimera checking/removal was performed using Minimap2 [[32]], and  
177 Minimap2 was also used to look for off-target hits containing human DNA ‘contaminated’  
178 reads by BLASTing reads against Genome Reference Consortium Human Build 38.p14. V3-  
179 V4 region trimmed reads were then clustered into ASVs ( $\leq 1$  nucleotide dissimilarity) using  
180 Divisive Amplicon Denoising Algorithm 2 (DADA2) [[33]], ASVs were taxonomically  
181 classified (to species level) using BLAST against the GreenGenes2 (GG2) database [[34]].



182 GG2 was chosen for its reliability (GG2 is a unified database suitable for whole genome  
183 sequencing (WGS) data and 16s data), as well as replicable results.

184

#### 185 Statistical analysis

186 Statistical analysis and data visualisation were done using the R Studio 4.2.3 package.  
187 Relative abundances of each genus were calculated in each sample, and a heatmap was  
188 constructed. Diversity index values were calculated using the Phyloseq package. Shannon,  
189 Chao1, Simpson and observed taxa values were used. These four values were analysed for  
190 statistical differences occurring between the *Blastocystis* positive and *Blastocystis* negative  
191 samples, as well as differences in diversity score between the ‘antibiotic positive’ time points  
192 (days 4-15) and the ‘antibiotic negative’ time points (day 0, 30 days post antibiotics and 3  
193 months post antibiotics). First, a Shapiro test was used to determine the data distribution to  
194 analyse the statistical differences between the sample groups. Normally distributed data was  
195 analysed with ANOVA test followed by Tukey HSD test for pairwise comparison. For  
196 samples with a non-normal distribution, the Kruskal-Wallis test was used, followed up by the  
197 Dunn Test (Bonferroni P-adjust) for pairwise comparisons. The raw diversity index values  
198 were also plotted over time. To visualise microbiome composition, compositional plots  
199 showing all taxa making up >1% of the total read counts were produced using the  
200 Microbiome package. To look for the presence of ‘bio-markers’ of the presence of  
201 *Blastocystis*, Linear Discriminant Effect Size (LEfSe) analysis was done [35]. LEfSe uses a  
202 combination of statistical tests to identify taxa whose high/low abundance or  
203 presence/absence allows for the best linear discrimination/explanation of the differences  
204 observed (changes in taxa) between the 2 groups of samples (*Blastocystis* +ve/-ve). Principle  
205 Component Analysis (PCA) was also used to determine differences between the *Blastocystis*

206 +ve/-ve groups based on overall taxa presence and distribution. Samples were plotted based  
207 on their Dissimilarity matrix values (Euclidian distances), and principal component analysis  
208 was performed. Statistical analysis was then done using PERMANOVA [[34]] to determine if  
209 the ‘centrons’ of each group (*Blastocystis* +ve/-ve) differed significantly in location.

210

#### 211 Metabolite extraction

212 200 mg solid stool stored in methanol or 200 µl liquid stool was resuspended in 4 ml  
213 methanol, then 200 mg glass beads were added and vortexed for 30 seconds. The samples  
214 were then incubated at RT for 3 minutes, then vortexed for a further 30 seconds. The  
215 supernatants were then divided in 4 x 1ml aliquots then centrifuged at 10,000 x g at 4°C for 20  
216 mins then lyophilized. The lyophilized desiccates were then resolubilised in 375 µl 10% D<sub>2</sub>O  
217 1 mM non-deuterated DSS and recombined to make 1.5 ml solutions for NMR analysis.

218 The extracts were run on a 600 MHz Avance III NMR spectrometer (Bruker) with QCI-P  
219 cryoprobe at a calibrated temperature of 298K to acquire 1D-<sup>1</sup>H spectra. For each sample an  
220 automated program was set up on the spectrometer using ICON NMR including measurement  
221 of water offset, 90° pulse calibration, locking to D<sub>2</sub>O, tuning and shimming using an  
222 excitation sculpting experiment. A 1D-<sup>1</sup>H-NOESY was run with a mixing time of 100 ms,  
223 512 scans and 8 dummy scans, a spectral width of 15.98 ppm (9.59 Hz), 32768 data points,  
224 an acquisition time of 2.27 s and a relaxation delay of 3 s.

225 The NMR spectra were phased, baseline corrected and had a 1 Hz exponential line  
226 broadening window function applied using TOPSPIN 3.6.1 (Bruker) software, then exported  
227 into Chenomx 8.4. The water resonance peak between 4.56 ppm and 4.97 ppm was deleted.  
228 The spectral peaks were then fit into the Chenomx library of metabolites using the profiler  
229 tool to match the peaks to their corresponding metabolites and concentrations.

230 Metabolites at significantly high abundances and of biological importance were divided into  
231 four groups; Short chain fatty acids (SCFAs), amino acids, sugars and sugar alcohols and  
232 other important metabolites and a time course was plotted to show the change in abundance  
233 of each metabolite throughout the antibiotic course.

234

## 235 **Results and Discussion**

### 236 **Composition of gut bacterial communities and *Blastocystis* colonisation**

237 Stool samples from days 0, 2, 3, 4, 5, 6, 7, 8, 10, 15, 30 days and 3 months after the start of  
238 the antibiotic course were collected and processed for both *Blastocystis* screening and 16S  
239 gut microbiome analysis. *Blastocystis* ST1 was present in samples from D2, D3 and  
240 consistently after D8 (**Table 1**).

241 For the microbiome analysis, the most abundant genera (defined here as taxa whose mean  
242 abundance across all samples exceeded 1% of the total read count) across all stool samples  
243 were plotted as a heatmap and compositional plot (**Figures 1 – 2**). Seventeen genera met  
244 these criteria, while multiple genera showed patterns of change throughout the antibiotic  
245 course, including *Phocaeicola\_A*, *Escherichia* and *Enterococcus\_B* (**Figures 1 – 2**). Samples  
246 were also grouped by their similarity values (Euclidean distance scores) and ordered in a  
247 dendrogram. The bacterial communities of the samples collected 30 days and three months  
248 after the start of the antibiotic course were more similar in taxonomic distribution to the  
249 samples taken at both ends of the antibiotic course (D0-2 and D10-15) and had the least  
250 similarity to samples taken on D3-D7 (**Figure 1**). The samples collected on D0 and D2 were  
251 strongly similar to each other. *Bacteroides* and *Phocaeicola* (both from the phylum  
252 *Bacteroidota*) were the most abundant genera. They became more dominant throughout the  
253 first week of the course, with their relative abundances decreasing in the months after the

254 completion of the course (**Figures 1 – 2**). *Phocaeicola* was the dominant genus and showed  
255 an increase in relative abundance in the first four days of the course, a slight decrease towards  
256 the end of the course and a further decrease in the months following the course (**Figure 2**).  
257 *Phocaeicola* was no longer the dominant genus after the antibiotic course, with *Escherichia*  
258 and *Enterococcus* being the most abundant in D30 and D3M, respectively (**Figure 2**).  
259 *Blastocystis* was not detected on D3, D4, D5, D6 and D7 of the course, but was again  
260 detected on D8 and recovered at the end. The presence of *Blastocystis* coincided with the  
261 decrease in abundance of *Bacteroides* and *Phocaeicola* (**Figure 2**). The reduced abundance  
262 of *Bacteroides* in the presence of *Blastocystis* is a consistent finding across studies globally  
263 [8], [14], [36], [37], [38], [39].

264

#### 265 **Impact of antibiotic course on alpha diversity**

266 To measure changes on alpha diversity, Shannon (factors in both evenness and richness),  
267 Chao1 (richness index which factors in potentially relevant singleton and doubleton ‘rare  
268 taxa’), Simpson (a measure of ‘dominance’/degree to which a few taxa make up most of the  
269 reads) and Observed taxa (true richness) indices were used. These diversity indices were  
270 analysed at the antibiotic-negative stage (pooled data of timepoints D0, D30, D3M) and at the  
271 antibiotic-positive stage (pooled data of timepoints D2, D3, D4, D5, D6, D7, D8, D10 and  
272 D15). All four metrics decreased during antibiotic administration. Antibiotics have been  
273 associated with acute gut microbiota perturbations defined by a decrease in taxonomic  
274 diversity [40], [41] (). However, these changes when analysed by ANOVA/Kruskal-Wallis  
275 were shown to be non-significant ( $>0.05$  P-value) (**Supplementary Figure 1 B,D,F,H**).

276 The diversity metric scores were also plotted individually over time. The Shannon and  
277 Simpson diversity metrics decreased during the antibiotic course however the baseline

278 composition recovered in the months after the course ended, although a decreasing trend was  
279 observed in D3M (**Figure 3 A, D**). This observation aligns with previous studies in both  
280 adults and children whereby core microbiome taxa return to their pre-antibiotics abundance  
281 [42]. Chao1 and Observed taxa showed sharp reductions at D4, D6 and D15. The reduction  
282 in these two indices on D15 contrasts the increase in the Shannon diversity score, indicating  
283 that the recovery in Shannon diversity score towards the end/post antibiotics course was  
284 characterised by a matching reduction in domination of the microbiome by a handful of taxa.  
285 This could be attributed to the elimination of rare taxa by the antibiotics.

286

### 287 **Alpha diversity of Gut Microbial communities and *Blastocystis* colonisation**

288 *Blastocystis* was detected early and later in the antibiotic course but not between D4 and D7  
289 (**Figure 3**). All examined metrics of alpha diversity of *Blastocystis*-positive stool were  
290 increased when compared to the *Blastocystis*-negative stool (**Figure 3; Supplementary**  
291 **Figure 1**). These changes in diversity were analysed for statistical significance and found to  
292 all be non-significant (Observed taxa and Chao1 showed very low P-values of 0.058 and  
293 0.064, respectively).

294

### 295 **Biomarker analysis of stool samples for *Blastocystis* colonisation**

296 Having shown that (non-significant) increases in diversity occur with the presence of  
297 *Blastocystis* in stool samples, LEfSe was used to look for biomarkers of this change. LEfSE  
298 [35] locates taxa whose presence/absence allows for the best identification of a member of  
299 the Blastopos group instead of a member of the Blastoneg group [35]. Any LDA score >2 or  
300 <-2 is considered to be significant (**Figure 4**) shows all taxa with a significant LDA score and  
301 are coloured to show the indicative group. As shown in the plot, only two taxa were

302 significantly viable at discriminating against the two groups in favour of *Blastocystis* negative  
303 samples (red, Blastoneg); these taxa were an unclassified member of the family  
304 *Anaerotignaceae* and the genus *Lactobacillus*. There was a considerably larger amount of  
305 taxa that were indicative of the *Blastocystis* positive group, with five taxa with a <-4 LDA  
306 score (**Supplementary Figure 2**); an unclassified member of the *Negativicutes* class of  
307 bacteria, an unclassified *Firmicute* bacteria, two different unclassified members of the family  
308 *Rikenellaceae* and an unclassified member of the family *Enterobacteriaceae*. The data  
309 suggests that some bacteria are indicators of the presence of *Blastocystis*. Still, the presence  
310 of so many indicative taxa may imply that a more diverse microbiome is the true indicative  
311 factor for *Blastocystis*.

312

### 313 **Impact of antibiotic course on metabolite composition of the gut and *Blastocystis*** 314 **colonisation**

315 The metabolite extracts from the stool samples were subjected to 1D <sup>1</sup>H NMR. Based on their  
316 chemical properties, four groups of metabolites were detected, including short-chain fatty  
317 acids (SCFAs) (**Figure 5a**), amino acids (**Figure 5b**), sugars and sugar alcohols (**Figure 5c**)  
318 and others (**Figure 5d**). Previous metabolome investigations at a single timepoint on  
319 *Blastocystis* positive and negative individuals showed a decreased abundance of certain  
320 metabolites in the former [2]. Specifically, Alanine, Glycine, Histidine, Isoleucine,  
321 Methionine, Threonine, Tryptophan and Valine all decreased, suggesting an anti-  
322 inflammatory role of *Blastocystis*. Significant increases in certain amino acids in the stool  
323 have been found in IBD patients [43]. Herein, in a time course metabolome of a single  
324 individual, all the amino acids, particularly Alanine and Valine, showed a decrease mid-  
325 course and recovery towards the end of the course.

326 Moreover, all amino acids, but glutamate showed a large decrease post-course (**Figure 5b**).  
327 Regarding SCFAs, the abundance of acetate increased throughout the first week of the  
328 antibiotic course but decreased during the second week and then recovered post-course.  
329 Butyrate increased after the first four days, decreased on D7, and recovered post-course.  
330 Whether these alterations reflect changes in absorption or loss remains an open question.  
331 Cellobiose was the most impacted sugar by the antibiotic course and showed a large increase  
332 in abundance during the first week, then decline and recovery during the second week  
333 (**Figure 5c**). Malonate steadily declined for the first five days and was undetectable by D6. It  
334 then recovered on D7, D8 and D10 but became undetectable on D15 and post-course (**Figure**  
335 **5d**). Succinate sharply increased from D1 to D2 and stayed high until D5, when it declined  
336 again. O-acetylcholine declined for the first five days then recovered on D6 and D7, but  
337 disappeared during the second week and didn't recover post-course. Notably, acetylcholine in  
338 the gut plays a role in intestinal homeostasis; hence, its disruption could potentially aggravate  
339 inflammation [44].

340

## 341 **Conclusion**

342 This case study provides valuable insights into the impact of antibiotic treatment on the  
343 presence of *Blastocystis* and the overall gut microbiome and metabolome. The 14-day course  
344 of Lansoprazole, Amoxicillin, and Clarithromycin significantly altered the gut microbial  
345 composition, causing a notable decline in microbial diversity mid-course and leading to a  
346 temporary absence of *Blastocystis*. Despite the antibiotic-induced perturbations, *Blastocystis*  
347 demonstrated resilience, re-emerging post-treatment.

348 Additionally, the study highlighted significant fluctuations in metabolite levels, including  
349 short-chain fatty acids and amino acids, which are critical for gut health. These changes

350 underscore the profound influence antibiotics have not only on microbial populations but also  
351 on the metabolic environment of the gut. While antibiotics did not have a lasting effect on  
352 *Blastocystis* colonisation, their temporary impact on microbial diversity and metabolite  
353 composition points to gut ecology's intricate and dynamic nature. The findings emphasise the  
354 need for careful consideration of antibiotic use, especially in conditions like IBS, where  
355 maintaining a balanced gut microbiome is crucial.

356 Future research should expand on these findings by exploring the long-term effects of  
357 antibiotics on gut microbiota and metabolites in larger cohorts. Understanding these  
358 interactions will be essential for developing targeted therapies that mitigate adverse impacts  
359 on the gut ecosystem while effectively treating gastrointestinal conditions.

360

### 361 **Acknowledgements**

362 We would like to thank the volunteer for participating in this study. Many thanks to the  
363 Tsaousis Lab members (2020 – 2021) for their help and support in sample collection and  
364 managing this project. J.M.N. was supported by a Kent Health studentship and W.J.S.E. by a  
365 SoCoBio DTP studentship.

366

### 367 **Contributions**

368 Conceptualisation, A.D.T.; methodology, J.M.N., W.J.S.E. and G.S.T.; software, G.S.T.;  
369 validation, G.S.T. and W.G. and W.J.S.E.; formal analysis, J.M.N. and W.J.S.E.;  
370 investigation, J.M.N. and W.J.S.E.; resources, A.D.T.; data curation, J.M.N. and E.G.;  
371 writing—original draft preparation, J.M.N.; writing—review and editing, A.D.T., E.G.;



372 supervision, A.D.T.; project administration, A.D.T.; funding acquisition, A.D.T. All authors  
373 have read and agreed to the published version of the manuscript.

374

375

376

377

## 378 **References**

379

- 380 [1] A. Visconti *et al.*, “Interplay between the human gut microbiome and host metabolism,” *Nat*  
381 *Commun*, vol. 10, no. 1, Dec. 2019, doi: 10.1038/s41467-019-12476-z.
- 382 [2] E. L. Betts *et al.*, “Metabolic fluctuations in the human stool obtained from blastocystis  
383 carriers and non-carriers,” *Metabolites*, vol. 11, no. 12, Dec. 2021, doi:  
384 10.3390/metabo11120883.
- 385 [3] K. S. W. Tan, “Blastocystis in humans and animals: New insights using modern  
386 methodologies,” *Vet Parasitol*, vol. 126, no. 1-2 SPEC.ISS., pp. 121–144, 2004, doi:  
387 10.1016/j.vetpar.2004.09.017.
- 388 [4] K. S. W. Tan, “New insights on classification, identification, and clinical relevance of  
389 Blastocystis spp.,” *Clin Microbiol Rev*, vol. 21, no. 4, pp. 639–665, 2008, doi:  
390 10.1128/CMR.00022-08.
- 391 [5] B. Skotarczak, “Genetic diversity and pathogenicity of blastocystis,” *Annals of Agricultural*  
392 *and Environmental Medicine*, vol. 25, no. 3, pp. 411–416, 2018, doi: 10.26444/aaem/81315.
- 393 [6] S. K. Kamaruddin, A. Mat Yusof, and M. Mohammad, “Prevalence and subtype distribution of  
394 Blastocystis sp. in cattle from Pahang, Malaysia,” *Trop Biomed*, vol. 37, no. 1, pp. 127–141,  
395 2020.
- 396 [7] J. G. Maloney *et al.*, “Identification and Molecular Characterization of Four New Blastocystis  
397 Subtypes Designated ST35-ST38,” *Microorganisms*, vol. 11, no. 1, Jan. 2023, doi:  
398 10.3390/microorganisms11010046.
- 399 [8] R. Y. Tito *et al.*, “Population-level analysis of Blastocystis subtype prevalence and variation in  
400 the human gut microbiota,” *Gut*, vol. 68, no. 7, pp. 1180–1189, Jul. 2019, doi: 10.1136/gutjnl-  
401 2018-316106.
- 402 [9] M. J. Kim, E. J. Won, S. H. Kim, J. H. Shin, and J. Y. Chai, “Molecular detection and  
403 subtyping of human blastocystis and the clinical implications: Comparisons between diarrheal

- 404 and non-diarrheal groups in Korean populations,” *Korean Journal of Parasitology*, vol. 58, no.  
405 3, pp. 321–326, 2020, doi: 10.3347/kjp.2020.58.3.321.
- 406 [10] C. R. Stensvold *et al.*, “Blastocystis: Unravelling potential risk factors and clinical significance  
407 of a common but neglected parasite,” *Epidemiol Infect*, vol. 137, no. 11, pp. 1655–1663, 2009,  
408 doi: 10.1017/S0950268809002672.
- 409 [11] A. M. Abdulsalam *et al.*, “Prevalence, predictors and clinical significance of Blastocystis sp. in  
410 Sebha, Libya,” *Parasit Vectors*, vol. 6, no. 86, pp. 1–8, 2013, doi: 10.1186/1756-3305-6-86.
- 411 [12] A. Alinaghizade, H. Mirjalali, M. Mohebali, C. R. Stensvold, and M. Rezaeian, “Inter- and  
412 intra-subtype variation of Blastocystis subtypes isolated from diarrheic and non-diarrheic  
413 patients in Iran,” *Infection, Genetics and Evolution*, vol. 50, pp. 77–82, 2017, doi:  
414 10.1016/j.meegid.2017.02.016.
- 415 [13] E. Piperni *et al.*, “Intestinal Blastocystis is linked to healthier diets and more favorable  
416 cardiometabolic outcomes in 56,989 individuals from 32 countries,” *Cell*, 2024, doi:  
417 10.1016/j.cell.2024.06.018.
- 418 [14] J. Forsell, J. Bengtsson-Palme, M. Angelin, A. Johansson, B. Evengård, and M. Granlund,  
419 “The relation between Blastocystis and the intestinal microbiota in Swedish travellers,” *BMC*  
420 *Microbiol*, vol. 17, no. 231, pp. 1–9, 2017, doi: 10.1186/s12866-017-1139-7.
- 421 [15] A. Kodio *et al.*, “Blastocystis colonization is associated with increased diversity and altered  
422 gut bacterial communities in healthy Malian children,” *Microorganisms*, vol. 7, no. 649, pp. 1–  
423 12, 2019, doi: 10.3390/microorganisms7120649.
- 424 [16] K.L Glassner, B.P Abraham, E.M.M. Quigley “The microbiome and inflammatory bowel  
425 disease,” *J Allergy Clin Immunol*, vol. 145, no. 1, pp. 16–27, Jan. 2020.
- 426 [17] C. Milani *et al.*, “The First Microbial Colonizers of the Human Gut: Composition, Activities,  
427 and Health Implications of the Infant Gut Microbiota,” *Microbiology and Molecular Biology*  
428 *Reviews*, vol. 81, no. 4, 2017, doi: 10.1128/mmbr.00036-17.
- 429 [18] P. Rutgeerts *et al.*, “Controlled trial of metronidazole treatment for prevention of Crohn’s  
430 recurrence after ileal resection,” *Gastroenterology*, vol. 108, no. 6, pp. 1617–1621, 1995, doi:  
431 10.1016/0016-5085(95)90121-3.
- 432 [19] L. R. Glick *et al.*, “Low-Dose Metronidazole is Associated with a Decreased Rate of  
433 Endoscopic Recurrence of Crohn’s Disease after Ileal Resection: A Retrospective Cohort  
434 Study,” *J Crohns Colitis*, vol. 13, no. 9, pp. 1158–1162, 2019, doi: 10.1093/ecco-jcc/jjz047.
- 435 [20] J. A. Yason, Y. R. Liang, C. W. Png, Y. Zhang, and K. S. W. Tan, “Interactions between a  
436 pathogenic Blastocystis subtype and gut microbiota: In vitro and in vivo studies,” *Microbiome*,  
437 vol. 7, no. 30, pp. 1–13, 2019, doi: 10.1186/s40168-019-0644-3.
- 438 [21] C. Audebert *et al.*, “Colonization with the enteric protozoa Blastocystis is associated with  
439 increased diversity of human gut bacterial microbiota,” *Sci Rep*, vol. 6, no. April, pp. 1–11,  
440 2016, doi: 10.1038/srep25255.
- 441 [22] H. Li *et al.*, “*Bifidobacterium* spp. and their metabolite lactate protect against acute  
442 pancreatitis via inhibition of pancreatic and systemic inflammatory responses,” *Gut Microbes*,  
443 vol. 14, no. 1, Dec. 2022, doi: 10.1080/19490976.2022.2127456.


- 444 [23] A. Sivan *et al.*, “Commensal *Bifidobacterium* promotes antitumor immunity and facilitates  
445 anti-PD-L1 efficacy,” *Science (1979)*, vol. 350, no. 6264, pp. 1084–1089, Nov. 2015, doi:  
446 10.1126/science.aac4255.
- 447 [24] K.T. Thia *et al.*, “Ciprofloxacin or metronidazole for the treatment of perianal fistulas in  
448 patients with Crohn’s disease: a randomized, double-blind, placebo-controlled pilot study,”  
449 *Inflamm Bowel Dis*, vol. 15, no. 1, pp. 17–24, 2009, doi: 10.1002/ibd.20608.
- 450 [25] B. Shen *et al.*, “A randomized clinical trial of ciprofloxacin and metronidazole to treat acute  
451 pouchitis,” *Inflamm Bowel Dis*, vol. 7, no. 4, pp. 301–305, 2001, doi: 10.1097/00054725-  
452 200111000-00004.
- 453 [26] B. E. Lacy, L. Chang, S. S. C. Rao, Z. Heimanson, and G. S. Sayuk, “Rifaximin Treatment for  
454 Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis  
455 Using New End Points,” *Clin Ther*, vol. 45, no. 3, pp. 198–209, Mar. 2023, doi:  
456 10.1016/j.clinthera.2023.01.010.
- 457 [27] M. Willmann *et al.*, “Distinct impact of antibiotics on the gut microbiome and resistome: A  
458 longitudinal multicenter cohort study,” *BMC Biol*, vol. 17, no. 1, Sep. 2019, doi:  
459 10.1186/s12915-019-0692-y.
- 460 [28] M. Reyman *et al.*, “Effects of early-life antibiotics on the developing infant gut microbiome  
461 and resistome: a randomized trial,” *Nat Commun*, vol. 13, no. 1, Dec. 2022, doi:  
462 10.1038/s41467-022-28525-z.
- 463 [29] T. Nogueira, P. H. C. David, and J. Pothier, “Antibiotics as both friends and foes of the human  
464 gut microbiome: The microbial community approach,” Feb. 01, 2019, *Wiley-Liss Inc.* doi:  
465 10.1002/ddr.21466.
- 466 [30] J. G. Caporaso *et al.*, “Global patterns of 16S rRNA diversity at a depth of millions of  
467 sequences per sample,” *Proc Natl Acad Sci U S A*, vol. 108, no. SUPPL. 1, pp. 4516–4522,  
468 Mar. 2011, doi: 10.1073/pnas.1000080107.
- 469 [31] E. Özkurt *et al.*, “LotuS2: an ultrafast and highly accurate tool for amplicon sequencing  
470 analysis,” *Microbiome*, vol. 10, no. 1, Dec. 2022, doi: 10.1186/s40168-022-01365-1.
- 471 [32] H. Li, “Minimap2: Pairwise alignment for nucleotide sequences,” *Bioinformatics*, vol. 34, no.  
472 18, pp. 3094–3100, Sep. 2018, doi: 10.1093/bioinformatics/bty191.
- 473 [33] B. J. Callahan, P. J. McMurdie, M. J. Rosen, A. W. Han, A. J. A. Johnson, and S. P. Holmes,  
474 “DADA2: High-resolution sample inference from Illumina amplicon data,” *Nat Methods*, vol.  
475 13, no. 7, pp. 581–583, Jul. 2016, doi: 10.1038/nmeth.3869.
- 476 [34] T. Z. DeSantis *et al.*, “Greengenes, a chimera-checked 16S rRNA gene database and  
477 workbench compatible with ARB,” *Appl Environ Microbiol*, vol. 72, no. 7, pp. 5069–5072, Jul.  
478 2006, doi: 10.1128/AEM.03006-05.
- 479 [35] N. Segata *et al.*, “Metagenomic biomarker discovery and explanation,” *Genome Biol*, vol. 12,  
480 no. 6, Jun. 2011, doi: 10.1186/gb-2011-12-6-r60.
- 481 [36] F. Beghini, E. Pasolli, T. D. Truong, L. Putignani, S. M. Cacciò, and N. Segata, “Large-scale  
482 comparative metagenomics of *Blastocystis*, a common member of the human gut  
483 microbiome,” *ISME Journal*, vol. 11, no. 12, pp. 2848–2863, Dec. 2017, doi:  
484 10.1038/ismej.2017.139.

- 485 [37] S. Gabrielli, F. Furzi, L. Fontanelli Sulekova, G. Taliani, and S. Mattiucci, “Occurrence of  
486 Blastocystis-subtypes in patients from Italy revealed association of ST3 with a healthy gut  
487 microbiota,” *Parasite Epidemiol Control*, vol. 9, May 2020, doi:  
488 10.1016/j.parepi.2020.e00134.
- 489 [38] L. O’Brien Andersen *et al.*, “Associations between common intestinal parasites and bacteria in  
490 humans as revealed by qPCR,” *European Journal of Clinical Microbiology & Infectious*  
491 *Diseases*, vol. 35, no. 9, pp. 1427–1431, Sep. 2016, doi: 10.1007/s10096-016-2680-2.
- 492 [39] A. Rajamanikam, M. N. M. Isa, C. Samudi, S. Devaraj, and S. K. Govind, “Gut bacteria  
493 influence Blastocystis sp. phenotypes and may trigger pathogenicity,” *PLoS Negl Trop Dis*,  
494 vol. 17, no. 3, 2023, doi: 10.1371/journal.pntd.0011170.
- 495 [40] L. McDonnell *et al.*, “Association between antibiotics and gut microbiome dysbiosis in  
496 children: systematic review and meta-analysis,” *Gut Microbes*, vol. 13, no. 1, pp. 1–18, 2021,  
497 doi: 10.1080/19490976.2020.1870402.
- 498 [41] W. E. Anthony *et al.*, “Acute and persistent effects of commonly used antibiotics on the gut  
499 microbiome and resistome in healthy adults,” *Cell Rep*, vol. 39, no. 2, Apr. 2022, doi:  
500 10.1016/j.celrep.2022.110649.
- 501 [42] A. Palleja *et al.*, “Recovery of gut microbiota of healthy adults following antibiotic exposure,”  
502 *Nat Microbiol*, vol. 3, no. 11, pp. 1255–1265, Oct. 2018, doi: 10.1038/s41564-018-0257-9.
- 503 [43] S. Bosch *et al.*, “Fecal Amino Acid Analysis Can Discriminate *De Novo* Treatment Naïve  
504 Pediatric Inflammatory Bowel Disease From Controls,” *J Pediatr Gastroenterol Nutr*, vol. 66,  
505 no. 5, pp. 773–778, May 2018, doi: 10.1097/MPG.0000000000001812.
- 506 [44] J. Uwada, H. Nakazawa, I. Muramatsu, T. Masuoka, and T. Yazawa, “Role of Muscarinic  
507 Acetylcholine Receptors in Intestinal Epithelial Homeostasis: Insights for the Treatment of  
508 Inflammatory Bowel Disease,” Apr. 01, 2023, *Multidisciplinary Digital Publishing Institute*  
509 *(MDPI)*. doi: 10.3390/ijms24076508.


510

**Table 1** *Blastocystis* colonisation of stool samples was collected on different dates of the antibiotic course, 30 days, and three months after the completion of the course. + indicates the sample is *Blastocystis* + and – indicates the sample is *Blastocystis* –.


Date of antibiotic course	<i>Blastocystis</i> +/-
Day 0	-
Day 2	+
Day 3	+
Day 4	-
Day 5	-
Day 6	-
Day 7	-
Day 8	+
Day 10	+
Day 15	+
30 days after course	+
3 months after course	+




**Figure 1.** Heatmaps showing the relative abundance of taxa within the faecal samples, shown are all taxa which made up >1% of the total reads, all samples are indicated to be *Blastocystis* +ve (blue) or -ve (red) by a colour-coordinated legend. Dendrograms cluster both taxa (A-B) and the samples (B) using Euclidean distances and clustered using optimal leaf ordering. A). Heatmap showing the samples ordered by their collection timepoint during the antibiotics course. B). The heat map shows the samples ordered based on their similarity.



**Figure 2.** (A-C). Compositional plots showing the bacterial composition of the gut taxa aggregated to varying taxonomic levels. A). Phylum level B). Genus level C). species level. Taxa included made up >1% of total read counts respectively. Taxa abundances are shown as % relative abundance.




**Figure 3.** Statistical Diversity analysis of samples taken throughout the antibiotics course. A,B,C,D). Shannon, Chao1, Observed (richness), Simpson scores over time. Indicated if the sample was +ve (blue) or -ve (red) for *Blastocystis*. Kruskal-Wallis H-test and Dunn’s test (Bonferroni p-adjust method) or ANOVA and Tukey-HSD test were used for statistical analysis (this was based on normality of the data, determined using the Shapiro test). Kruskal Wallis/ANOVA scores were all shown to be  $>0.05$  indicating no-significance between the samples.



**Figure 4.** Linear Discriminant Analysis (LDA) Effect Size (LEfSe) plot. LDA scores indicate the presence/increased abundance of each taxa to discriminate between two conditions, *Blastocystis* +ve (blue) and *Blastocystis* -ve (red). Taxa with LDA scores between -2 and 2 are considered insignificant 'biomarkers' and are not included in the plot.





**Figure 5** Time course of metabolite abundances of four different groups of metabolites throughout the antibiotic course as well as *Blastocystis* Colonisation. a. SCFAs b. Amino acids. c. Sugars and Sugar alcohols d. Other important metabolites